Age influences magnitude but not duration of response to levodopa.
- 1 January 1993
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 56 (1) , 65-68
- https://doi.org/10.1136/jnnp.56.1.65
Abstract
Following an all-night fast, 45 patients with Parkinson's disease were examined using certain motor items present in the United Parkinson's Disease Rating Scale. All were given a single tablet of carbidopa 25 mg and levodopa 250 mg and re-examined 90 minutes later. In addition to this evaluation, 23 of these patients underwent further scoring over a 4-hour period. A significant negative correlation was found between age and one important aspect of drug-derived benefit: magnitude of response. In contrast, age had no apparent influence on duration of benefit from the drug. Although baseline (fasting) scores were predictably correlated with duration of disease, magnitude of response was not adversely influenced by this variable. Not all Parkinsonian signs were equally influenced by age. Whereas the poor response of gait and bradykinesia appeared to be dependent on age, no such effect was noted on rest tremor scores. The data indicate that in patients with Parkinson's disease treated long term, factors associated with age rather than duration of disease may have a stronger adverse influence on magnitude of response to levodopa.Keywords
This publication has 24 references indexed in Scilit:
- Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- Magnitude of Response to Levodopa in Parkinson Disease as It Relates to Peripheral and Central Measurements of Levodopa and Associated MetabolitesClinical Neuropharmacology, 1989
- Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1989
- On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamicsAnnals of Neurology, 1987
- Individual manifestations of Parkinson's disease after ten or more years of levodopaMovement Disorders, 1986
- Age‐Correlated Loss of Dopaminergic Binding Sites in Human Basal GangliaJournal of Neurochemistry, 1982
- Dementia in Parkinson diseaseAnnals of Neurology, 1979
- SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASEThe Lancet, 1977
- SUSTAINED LEVODOPA THERAPY IN PARKINSONISMThe Lancet, 1973
- CLINICAL ANALYSES OF FACTORS INFLUENCING L‐DOPA TREATMENT OF PARKINSON'S SYNDROMEActa Medica Scandinavica, 1972